Search bioRxivSearch

bioRxiv · 10.1101/052944

Potential impact of novel diagnostics and treatments on the burden of antibiotic resistant in Escherichia coli

Abstract

The rising threat of antibiotic resistance in Europe and beyond is of increasing concern and is prompting renewed effort to better understand and mitigate their impact. Escherichia Coli blood stream infections are a more major concern in Europe given their incidence and severe associated outcomes. Additionally the level of 3rd generation cephalosporins and carbapenems resistance among those bacteraemia has significantly increased, limiting available treatment options. We estimated the current burden associated with E. coli blood stream infections in Europe at 17,000 (95%CI [8,000; 30,000]) excess deaths and 960,000 (95%CI [600,000; 1,450,000]) extra hospital bed days. From those, the contribution due to 3rd generation cephalosporins and carbapenems resistant strains reached 6,000 (95%CI [2,000; 12,000]) excess deaths, and 200,000 (95%CI [76,000; 420,000]) extra hospital bed stay. In the worst case scenario, we estimated the burden of E. coli blood stream infection in 2026 could increase over 4-fold, mostly resulting from an increase in the level of resistance rather than an increase in the incidence of blood stream infections. Finally, we estimated that the impact of combined novel diagnostics and treatments could substantially reduce the excess mortality by 18.5% to 55.5%, and length of stay by 13.2% to 75.6%.

Explore related subjects

Keep this discovery

BibTeXRIS

Pierre Nouvellet, Julie Robotham, Nichola R Naylor, Neil Woodford, Neil M Ferguson. 2016-05-13. Potential impact of novel diagnostics and treatments on the burden of antibiotic resistant in Escherichia coli. https://doi.org/10.1101/052944

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

A risk stratification approach for improved interpretation of diagnostic accuracy statistics

Diagnostic accuracy statistics, including predictive values, risk-differences, Youdens index and Area Under the Curve (AUC), assess the promise of novel biomarkers proposed as diagnostic tests. We reinterpret these statistics in light of risk-stratification (how well a biomarker separates those at higher risk from those at lower risk) to better understand their implications for public-health programs. We introduce an intuitively simple statistic, Mean Risk Stratification (MRS): the average change in risk (pre-test vs. post-test) revealed for tested individuals. High MRS implies better risk separation achieved by testing. MRS demonstrates that conventional predictive values can mislead because they do not account for disease prevalence or test-positivity rates. Little risk-stratification is possible for rare diseases, demonstrating a \"high-bar\" to justify population-based screening. Importantly, we demonstrate that the risk-difference, Youdens index, and AUC measure only multiplicative relative gains in risk-stratification: AUC=0.6 achieves only 20% of maximum risk-stratification (AUC=0.9 achieves 80%). However, large relative gains in risk-stratification might not imply large absolute gains if disease is rare or if the test is rarely positive. We illustrate MRS by our experience comparing the performance of cervical cancer screening tests in China vs. the USA. The test with the worst AUC=0.72 in China (visual inspection with ascetic acid) provides twice the risk-stratification of the test with best AUC=0.83 in the USA (human papillomavirus and Pap cotesting) because China has three times more cervical precancer/cancer. MRS could be routinely calculated to better understand the clinical/public-health implications of standard diagnostic accuracy statistics.

Epidemiology

Collider Scope: How selection bias can induce spurious associations

Large-scale cross-sectional and cohort studies have transformed our understanding of the genetic and environmental determinants of health outcomes. However, the representativeness of these samples may be limited - either through selection into studies, or by attrition from studies over time. Here we explore the potential impact of this selection bias on results obtained from these studies, from the perspective that this amounts to conditioning on a collider (i.e., a form of collider bias). While it is acknowledged that selection bias will have a strong effect on representativeness and prevalence estimates, it is often assumed that it should not have a strong impact on estimates of associations. We argue that because selection can induce collider bias (which occurs when two variables independently influence a third variable, and that third variable is conditioned upon), selection can lead to substantially biased estimates of associations. In particular, selection related to phenotypes can bias associations with genetic variants associated with those phenotypes. In simulations, we show that even modest influences on selection into, or attrition from, a study can generate biased and potentially misleading estimates of both phenotypic and genotypic associations. Our results highlight the value of knowing which population your study sample is representative of. If the factors influencing selection and attrition are known, they can be adjusted for. For example, having DNA available on most participants in a birth cohort study offers the possibility of investigating the extent to which polygenic scores predict subsequent participation, which in turn would enable sensitivity analyses of the extent to which bias might distort estimates.\n\nKey MessagesSelection bias (including selective attrition) may limit the representativeness of large-scale cross-sectional and cohort studies.\n\nThis selection bias may induce collider bias (which occurs when two variables independently influence a third variable, and that variable is conditioned upon).\n\nThis may lead to substantially biased estimates of associations, including of genetic associations, even when selection / attrition is relatively modest.

Epidemiology

A comparative analysis of Chikungunya and Zika transmission

The recent global dissemination of Chikungunya and Zika has fostered public health concern worldwide. To better understand the drivers of transmission of these two arboviral diseases, we propose a joint analysis of Chikungunya and Zika epidemics in the same territories, taking into account the common epidemiological features of the epidemics: transmitted by the same vector, in the same environments, and observed by the same surveillance systems. We analyse eighteen outbreaks in French Polynesia and the French West Indies using a hierarchical time-dependent SIR model accounting for the effect of virus, location and weather on transmission, and based on a disease specific serial interval. We show that Chikungunya and Zika have similar transmission potential in the same territories (transmissibility ratio between Zika and Chikungunya of 1.04 [95% credible interval: 0.97; 1.13]), but that detection and reporting rates were different (around 19% for Zika and 40% for Chikungunya). Temperature variations between 22{degrees}C and 29{degrees}C did not alter transmission, but increased precipitation showed a dual effect, first reducing transmission after a two-week delay, then increasing it around five weeks later. The present study provides valuable information for risk assessment and introduces a modelling framework for the comparative analysis of arboviral infections that can be extended to other viruses and territories.

Epidemiology